A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma-Reference-Cited by-同舟云学术

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

Published:2014-04-23 Issue:5b Volume:113 Page:E137-E143
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Pond Gregory R.¹,Agarwal Neeraj²,Bellmunt Joaquim³,Choueiri Toni K.⁴,Qu Angela⁵,Fougeray Ronan⁵,Vaughn David⁶,James Nicholas D.⁷,Salhi Yacine⁵,Albers Peter⁸,Niegisch Günter⁸,Galsky Matthew D.⁹,Wong Yu-Ning¹⁰,Ko Yoo-Joung¹¹,Stadler Walter M.¹²,O'Donnell Peter H.¹²,Sridhar Srikala S.¹³,Vogelzang Nicholas J.¹⁴,Necchi Andrea¹⁵,Di Lorenzo Giuseppe¹⁶,Sternberg Cora N.¹⁷,Mehta Amitkumar¹⁸,Sonpavde Guru¹⁸

Affiliation:

1. Ontario Clinical Oncology Group; McMaster University; Hamilton ON Canada

2. Department of Medicine; Section of Hematology-Oncology Huntsman Cancer Institute; University of Utah; Salt Lake City UT USA

3. University Hospital del Mar-IMIM; Barcelona Spain

4. Department of Medicine; Section of Hematology-Oncology Dana-Farber Cancer Institute and Harvard Medical School; Boston MA USA

5. Institut de Recherche Pierre Fabre; Boulogne France

6. Department of Medicine; Section of Hematology-Oncology University of Pennsylvania; Philadelphia PA USA

7. University of Birmingham; Birmingham UK

8. Heinrich Heine University; Dusseldorf Germany

9. Department of Medicine; Section of Hematology-Oncology Tisch Cancer Center Institute; Mount Sinai School of Medicine; New York NY

10. Department of Medicine; Section of Hematology-Oncology Fox Chase Cancer Center; Philadelphia PA USA

11. Sunnybrook Odette Cancer Centre; Toronto ON Canada

12. Department of Medicine; Section of Hematology-Oncology University of Chicago; Chicago IL USA

13. Princess Margaret Hospital; Toronto ON Canada

14. Comprehensive Cancer Centers of Nevada; Las Vegas NV USA

15. Fondazione IRCCS Istituto Nazionale dei Tumori; Milan

16. University Federico II; Naples

17. San Camillo and Forlanini Hospitals; Rome Italy

18. Department of Medicine; Section of Hematology-Oncology UAB (University of Alabama at Birmingham) Comprehensive Cancer Center; Birmingham AL USA

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12564/fullpdf

Reference25 articles.

1. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium;Sonpavde;Lancet Oncol,2010

2. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy;Beer;Clin Genitourin Cancer,2008

3. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer;Choueiri;J Clin Oncol,2012

4. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen;Culine;Br J Cancer,2006

5. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium;Petrylak;BJU Int,2009

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma;Targeted Oncology;2024-05-28

3. Surgical Treatment of Solitary Metachronous Adrenal Metastasis from Urothelial Carcinoma of the Urinary Bladder;European Endocrinology;2023

4. A Platinum Resistance-Related lncRNA Signature for Risk Classification and Prognosis Prediction in Patients with Serous Ovarian Cancer;Journal of Oncology;2022-11-09

5. First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis;Journal of Immunotherapy;2022-09-20